Mecasermin vs igf-1 lr3

Mecasermin (S-tier) vs igf-1 lr3 (F-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

Mecasermin · tier S

Mecasermin is recombinant human IGF-1 approved as subcutaneous Increlex for a narrow pediatric severe-primary-IGF-1-deficiency indication. It is not a general height, adult-wellness, or muscle drug.

Subcutaneous mecasermin increases growth velocity in children who meet the severe-primary-IGF-1-deficiency or GH-antibody indication. The mostly open-label disease-specific evidence does not support ordinary short stature, adult height gain, bodybuilding, anti-aging, or IGF-1 LR3.

8.0 cm/year mean first-year velocity in the pooled severe-deficiency program · half-life 5.8 h after the specified subcutaneous Increlex exposure in a three-child cohort · growth hormone

igf-1 lr3 · tier F

a free-circulating IGF-1 analog for muscle growth. sustained IGF-1 elevation carries one of the clearer cancer-risk signals in the literature.

a free-circulating IGF-1 analog. anabolic signal is real; sustained IGF-1 elevation carries one of the clearer cancer-risk signals in the literature.

WADA S2 banned in sport · half-life ~1-2 hours, estimated (no human PK); NOT long-acting, LR3 escapes the IGF-binding proteins that give complex-bound native IGF-1 its ~12-15h half-life · growth hormone

at a glance

• Mecasermin: tier S · 8.0 cm/year mean first-year velocity in the pooled severe-deficiency program
• igf-1 lr3: tier F · WADA S2 banned in sport

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.